Early buyers will receive 10% customization on reports.. Based on technology, the polymerase chain reaction (PCR) segment accounted for the largest share of the market in 2016. On the basis of technology, the companion diagnostics market is broadly segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), and other technologies. In 2016, the polymerase chain reaction (PCR) segment accounted for the largest share of this market and the next-generation sequencing (NGS) segment is expected to register the highest CAGR during the forecast period. The large share of the PCR segment is attributed to its ease of use and to the fact that it does not require many samples for biomarker identification.. Based on indication of companion diagnostics market, the oncology segment held the largest market share in 2016. Based on the indication, the global companion diagnostics market is divided into oncology, infectious diseases, ...
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has entered into a master collaboration agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lillys past work together. Companion diagnostics unlock a patients molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed.. The agreement provides a framework for Lilly and QIAGEN to collaborate on future projects - across all of Lillys therapeutic areas - aimed at bringing to market Lilly medicines paired with QIAGEN diagnostics. It also further underscores QIAGENs leading position in partnering with global pharmaceutical companies to deliver the benefits of personalized medicine to patients and healthcare providers.. "Tailored therapies are ...
According to the latest report published by Credence Research, Inc. "Companion Diagnostics Market - (Technology Type - Polymerase Chain Reaction, Immunohistochemistry, In-situ Hybridization Test, Gene Sequencing and Others; Indication Type - Oncology, Cardiovascular Diseases, Infectious Diseases and Autoimmune Diseases): Growth, Future Prospects and Competitive Analysis, 2016-2023," the market was valued at USD 3,717.2 Mn in 2015, and is expected to reach USD 14,453.3 Mn by 2023, expanding at a CAGR of 18.5% from 2016 to 2023.. Market Insights Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. On the basis of technology the companion diagnostics market has been ...
According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $2.62 billion in 2015 and is expected to reach $9.27 billion by 2022 growing at a CAGR of 19.78% during the forecast period. At present, increasing demand for personalized medicine is mostly contributing to the global companion diagnostics market growth. On the other hand,…
The primary aim of the molecular pathology laboratory is to provide clinical diagnostic/prognostic services for the molecular analysis of clinical material submitted to the anatomical and clinical laboratories of the Temple University Hospital. The goal of the molecular pathology rotation is to provide a comprehensive understanding of the role of molecular pathology in clinical and anatomic pathology. Residents rotating through the molecular pathology laboratory are given extensive handouts on the theoretical basis underlying the principle of the polymerase chain reaction (PCR). In addition, these handouts also include topics such as real-time PCR, FRET (fluorescence resonance energy transfer) analysis, cDNA microarrays, etc. They are trained to perform as well as interpret the molecular diagnostic test results. The primary testing in the molecular diagnostics laboratory are viral loads and genotyping for HIV-1 and HCV and HPV genotyping. Other assays include hypercoagulation assays for Factor V ...
Global Companion Diagnostics Market By Product and Services (Assay Kits and Reagents, Software & Services), Technology (Polymerase Chain Reaction, Molecular Diagnostics, FISH, CISH, Immunohistochemistry, Real-time PCR, Next-Generation Sequencing, Gene Sequencing, In Situ Hybridization), Application (Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, Urology, Gastric Cancer), Indication (Oncology {Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma} Neurology, Infectious Diseases), End Users (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories), Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa)- Industry Trends and Forecast to 2026 - Industry Trends and Forecast to 2026
According to a new market report published by Transparency Market Research "Molecular Diagnostics Market (PCR, Next Generation Sequencing, Microarray, Infectious diseases, Genetic disease, Oncology testing, Blood donor screening) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global molecular diagnostics market was valued at USD 4.3 billion in 2012 and is expected to grow at a CAGR of 11.1 % from 2013 to 2019, to reach an estimated value of USD 8.7 billion in 2019.. Browse Molecular Diagnostics Market Report with Full TOC at http://www.transparencymarketresearch.com/molecular-diagnostics-industry.html. Molecular diagnostics is defined as a class of diagnostic tests that identifies proteins or nucleic acid at a molecular level. This class of test assists in identification of genetic markers of patient or nucleic acids in foreign organism. Currently, molecular diagnostics forms relatively a small portion of the overall diagnostics market but is identified ...
Dear Diagnostic Molecular Pathology reader, This letter is to notify you that Lippincott Williams & Wilkins will be merging the publication of Diagnostic Molecular Pathology with Applied Immunohistochemistry & Molecular Morphology (AIMM) effective with the January 2014 issue. AIMM will now increase its publication to 10 issues per year and broaden its scope and content to provide complete coverage of the diagnostic, prognostic and predictive applications of immunohistochemistry (IHC) and molecular pathology, with an emphasis on applications of diagnostic import. The focus is on the understanding of the biology of tumors and other lesions, and provide up to date information of diagnostic and scientific relevance to practicing and research pathologists.. Please note that the DMP archive will be available on the AIMM website, appliedimmunohist.com. We want to thank you for being dedicated readers of Diagnostic Molecular Pathology, and encourage you to subscribe to the new journal, Applied ...
Neutrolis is developing therapeutic candidates and companion diagnostics, for the treatment and diagnosis of inflammatory diseases, such as systemic lupus
What is the future of personalized medicine? Featuring Dr. Trevor Hawkins (An Introduction to Companion Diagnostics), Dr. Patrick Joseph (Making It Personal for Patients), and Dr. Richard Fra
Companion diagnostics is an in vitro medical device that provides information about the patients who are likely to benefit from a particular therapeutic product and also provides information about the biological products or corresponding drug if they are safe and effective for use. It also identifies patients that a...
Companion diagnostics market to reach $6,452 million by 2026, with a growing CAGR of 18.3%. PCR segment dominates the global market.
NEW YORK, Nov. 17, 2016 /PRNewswire/ -- The Companion Diagnostics (CDx) Market Forecast 2016-2026: Leading Companies, Trends and Developments in the...
Press release - Future Market Insights - Companion Diagnostics Market to Witness Exponential Growth by 2026 - published on openPR.com
Companion Diagnostics Market was Valued At USD 3,717.2 Mn In 2015, And Is Expected To Reach USD 14,453.3 Mn By 2023, Expanding At A CAGR Of 18.5% From 2016 To 2023.
Asuragen and Illumina collaborate to set up a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies.
Global Molecular Diagnostics market has generated a revenue of US$10.85 billion in 2019, and is estimated to be just over US$15 billion in 2020. During 2019 to 2022 period, which is said to be influenced by the COVID-19 pandemic, Infectious Diseases (driven by COVID-19 Diagnostics) segment is anticipated to gain rapid demand, growing at a robust CAGR of 14.9%. Infectious Diseases segment, in which COVID-19 testing is a part, is estimated to generate an extra revenue of US$3.8 billion globally in 2020 compared to 2019.. Molecular Diagnostics technologies market explored in this report includes PCR Polymerase Chain Reaction (PCR), Sequencing, Hybridization and Others comprising Microarrays, Nanotechnology etc. The study includes the market analysis for Molecular Diagnostics product types - Reagents and Consumables, Instruments and Software & Services. The study also explores the market analysis for Molecular Diagnostics End-Use sectors comprising Hospitals & Diagnostics Labs, Research Institutes & ...
A recent report by Fact.MR projects the global colorectal cancer diagnostics market to register an impressive expansion at 8.5% CAGR during the forecast period 2017 to 2022. Revenues from the global colorectal cancer diagnostics market is expected to surpass US$ 2,000 Mn by 2022-end.. There has been a substantial increase in the demand for the colorectal cancer diagnostics, with the outbreak of colon cancer at an alarming rate. Rise in the demand for the diagnostics equipment is evident in the emerging countries, deprived of the robust healthcare infrastructures. Additionally, absence of adjuvant and neoadjuvant agents for the detection of cancer among patients is expected to reflect favorably on the global colorectal cancer diagnostics market.. Request Sample Here: https://www.factmr.com/report/70/colorectal-cancer-diagnostics-market. With the advent of advanced diagnostics tests, government initiatives to control the prevalence of cancer, and adoption of diagnostics therapies, the size of the ...
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the then-emerging field of molecular diagnostics. Through its Board of Directors and Committees, AMP pursues topics of importance to those at the forefront of this growing discipline. From the beginning, AMP has worked to develop mechanisms for training and certification in diagnostic molecular pathology. AMP has assumed national visibility with its efforts to shape regulations and policy that influence research and the practice of molecular diagnostics. The organization is divided into the scientific subdivisions of genetics, infectious diseases, hematopathology, and solid tumors. Each subdivision addresses issues, identifies goals, shapes policy, and provides member benefits specific to that particular discipline. Members can participate in any or all of these subdivisions. ...
Table of Content:. 1. INTRODUCTION. 1.1. OVERVIEW OF THE GLOBAL CANCER DIAGNOSTICS MARKET. 1.2. CURRENCY AND PRICING. 1.3. LIMITATION. 1.4. MARKETS COVERED. 2. MARKET SEGMENTATION. 2.1. KEY TAKEAWAYS. 2.2. ARRIVING AT THE GLOBAL CANCER DIAGNOSTICS MARKET SIZE. 2.2.1. MARKET CRACKDOWN APPROACH. 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS. 2.2.3. DATA TRIANGULATION. 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES. 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES. 2.2.6. PORTERS FIVE FORCES MATRIX. 2.2.7. PEST ANALYSIS. 2.2.8. EPIDEMIOLOGY FORECASTING MODELS. 2.3. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH SNAPSHOT. 2.4. ASSUMPTIONS. 3. MARKET OVERVIEW. 3.1. DRIVERS. 3.2. RESTRAINTS. 3.3. OPPORTUNITIES. 3.4. CHALLENGES. 4. EXECUTIVE SUMMARY. 5. PREMIUM INSIGHTS. 6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY. 6.1. OVERVIEW 6.2. PLATFORM BASED, BY PRODUCT TYPE. 6.2.1. POLYMERASE CHAIN REACTION (PCR). 6.2.2. IN SITU HYBRIDIZATION (ISH). 6.2.3. IMMUNOHISTOCHEMISTRY (IHC). 6.2.4. NEXT GENERATION ...
Table of Content:. 1. INTRODUCTION. 1.1. OVERVIEW OF THE GLOBAL CANCER DIAGNOSTICS MARKET. 1.2. CURRENCY AND PRICING. 1.3. LIMITATION. 1.4. MARKETS COVERED. 2. MARKET SEGMENTATION. 2.1. KEY TAKEAWAYS. 2.2. ARRIVING AT THE GLOBAL CANCER DIAGNOSTICS MARKET SIZE. 2.2.1. MARKET CRACKDOWN APPROACH. 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS. 2.2.3. DATA TRIANGULATION. 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES. 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES. 2.2.6. PORTERS FIVE FORCES MATRIX. 2.2.7. PEST ANALYSIS. 2.2.8. EPIDEMIOLOGY FORECASTING MODELS. 2.3. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH SNAPSHOT. 2.4. ASSUMPTIONS. 3. MARKET OVERVIEW. 3.1. DRIVERS. 3.2. RESTRAINTS. 3.3. OPPORTUNITIES. 3.4. CHALLENGES. 4. EXECUTIVE SUMMARY. 5. PREMIUM INSIGHTS. 6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY. 6.1. OVERVIEW 6.2. PLATFORM BASED, BY PRODUCT TYPE. 6.2.1. POLYMERASE CHAIN REACTION (PCR). 6.2.2. IN SITU HYBRIDIZATION (ISH). 6.2.3. IMMUNOHISTOCHEMISTRY (IHC). 6.2.4. NEXT GENERATION ...
Brain cancer diagnostics Market: Overview. Brain cancer diagnostics market is expected to expand at healthy growth rates across regions.In the U.S. alone the American Brain Tumor Association has predicted that nearly 78,000 new cases of primary brain tumors are expected to be diagnosed this year. Malignant brain tumors are the most common cause of cancer-related mortality in patients aged 15-39 years. It is also one of the most common cancers affecting 15-19-year-olds. The markets in European region too are expected to witness rising number of diagnosed cases given a cross-sectional aging in population levels. The diagnosis of meningioma followed by glioma and glioblastoma are expected to witness acceleration in the U.S. and EU5 countries.. Brain Cancer Diagnostics Market: Region-wise Outlook. Depending on the geographic region, Brain cancer diagnostics market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia-Pacific excluding Japan, Japan, ...
Press Release issued Sep 16, 2013: Reportstack, provider of premium market research reports announces the addition of 2014 Opportunities in the Spanish Cancer Diagnostics Market market report to its offering 2014 Opportunities in the Spanish Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Spanish cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
Results RNA yield was considerably lower in core biopsies, but sufficient to measure the assay in all samples. The EndoPredict score was highly correlated between paired samples (Pearson r=0.92), with an excellent concordance of classification into a low or high risk of metastasis (overall agreement 95%). ...
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of companion diagnostics market. Chapter 3 provides a general introduction on personalized medicine. We have also explained, in detail, companion diagnostics and their development from pharmacogenomics biomarkers. Chapter 4 analyzes the global companion drugs market, including the FDA and EMA approved companion drugs. The chapter provides details on leading companion drugs and indications. It also highlights leading pharmaceutical companies active in this market, along with case studies of some well-known companion drugs. Chapter 5 analyzes the global companion diagnostics market, identifying the currently marketed diagnostics and those in the pipeline. In this chapter, we have included our estimates on how the overall market is going to evolve globally over the next ten years. We adopted a bottom-up approach to forecast details on the number of tests and ...
Brace for impact. Moving to a classification system for IVDs allows for the regulatory framework to remain more agile as technology develops. For newly classified B to D IVDs, the classification changes are significant for the industry, as there may be further administrative burdens on many small- and medium-sized companies in this sector. The change will require involvement of notified bodies during the conformity assessment before a product can be placed on the market, and for many IVD manufacturers this will be a new experience.. For companion diagnostics, the changes under the new regulation are even more significant as many of these IVDs are currently self-certified. The new regulation introduces a definition and special provisions for companion diagnostics, to be regulated as Class C. In addition, for companion diagnostics, the proposed regulatory changes include European Medical Agency (EMA) involvement. This unique requirement has caused industry concern since the EMA are likely to be ...
The latest market report published by Credence Research, Inc. "Global Molecular Diagnostics Market - Market Growth, Future Prospects, Competitive Analysis, 2017 - 2025," the global molecular diagnostics market was valued at US$ 6,077.9 Mn in 2016, and is expected to reach US$ 12,358.6 Mn by 2025 expanding at a CAGR of 7.8 % from 2017 to 2025.. Browse the full report Global Molecular Diagnostics Market - Market Growth, Future Prospects, Competitive Analysis, 2017 - 2025 at http://www.credenceresearch.com/report/molecular-diagnostic-market. Market Insights. Molecular diagnostic has undergone tremendous technological advancement due to the growing need for personalized medication, rapid diagnosis to determine antibiotic regimen in order to prevent drug resistance and for the in-depth study of pandemic diseases such as Cholera, Swine flu, Dengue and Hepatitis A. In 2016, the reagents and kits held the largest revenue share for the product segment due to factors such as increasing number of clinics ...
The latest market report published by Credence Research, Inc. "Global Molecular Diagnostics Market - Market Growth, Future Prospects, Competitive Analysis, 2017 - 2025," the global molecular diagnostics market was valued at US$ 6,077.9 Mn in 2016, and is expected to reach US$ 12,358.6 Mn by 2025 expanding at a CAGR of 7.8 % from 2017 to 2025.. Browse the full report Global Molecular Diagnostics Market - Market Growth, Future Prospects, Competitive Analysis, 2017 - 2025 at http://www.credenceresearch.com/report/molecular-diagnostic-market. Market Insights. Molecular diagnostic has undergone tremendous technological advancement due to the growing need for personalized medication, rapid diagnosis to determine antibiotic regimen in order to prevent drug resistance and for the in-depth study of pandemic diseases such as Cholera, Swine flu, Dengue and Hepatitis A. In 2016, the reagents and kits held the largest revenue share for the product segment due to factors such as increasing number of clinics ...
NEW YORK, Dec. 29, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:. Molecular Diagnostics in Cancer Testing. http://www.reportlinker.com/p0171427/Molecular-Diagnostics-in-Cancer-Testing.html. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) ...
Molecular diagnostics is one of the most transformative and dynamic areas of diagnostics. It is a technique used for analyzing biological markers in proteome and genome. Molecular diagnostics tests are increasingly used in oncology, infectious disease, pharmacogenomics, and human leukocyte antigen typing. Oncology molecular diagnostics is a major application of molecular biology and is increasin
The Global Molecular Diagnostics Market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.. Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also ...
The Global Molecular Diagnostics Market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.. Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also ...
Molecular diagnostics is a set of methods used to examine Biological genome and proteome markers by applying molecular biology to medical tests- the genetic code of the organism and how their cells express their genes as proteins. During the 1990s, the discovery of newly discovered genes and new DNA sequencing techniques led to the emergence of a distinct field of molecular and genomic laboratory medicine; in 1995, the Molecular Pathology Association (AMP) was formed to give it structure. In vitro biological assays such as PCR-ELISA or in situ fluorescence hybridization are used in molecular diagnostics. The test identifies a molecule that is a disease marker or risk in a sample taken from a patient, often in low concentrations.. The other growth factors of molecular diagnostic market are; rising global economy, increasing healthcare expenditure by public and private partnership model, increasing out of pocket expenditure, expansion of reimbursement policies, increasing healthcare insurance ...
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion ...
LONDON - At present, the cancer diagnostics market is on the verge of explosion. Numerous remarkable technological breakthroughs have been recently achieved in the tumor diagnosis and therapy field; various new specific antigens have been discovered and the mystery of the diseases genetic basis has been unlocked.. In the next five years, the worlds market for cancer diagnostics is promising to perform as exciting, rapidly evolving and dynamic field. Projected technological breakthroughs are expected to open a wide range of new lucrative opportunities for detecting specific tumors, determining genetic predisposition as well as for monitoring biological response to cancer therapy.. Increasing number of geriatric population worldwide is predicted to give further boost to the demand for malignancy assays and, thus, rapid market expansion at the global level.. Cutting-edge research report "2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales ...
2016-2020 Denmark Cancer Diagnostics Market: Emerging Cancer Diagnostics, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains-Test Volume and Sales Forecasts, Competitive Strategies, Opportunities for Suppliers Published by VPGMarketResearch.com at researchbeam.com 535 Pages
[535 Pages Report] Check for Discount on 2016-2020 Canada Cancer Diagnostics Market: Emerging Cancer Diagnostics, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains report by Venture Planning Group. ...
Molecular pathology is an emerging discipline within pathology which is focused in the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids.[1] Molecular pathology shares some aspects of practice with both anatomic pathology and clinical pathology, molecular biology, biochemistry, proteomics and genetics, and is sometimes considered a "crossover" discipline. It is multi-disciplinary in nature and focuses mainly on the sub-microscopic aspects of disease. A key consideration is that more accurate diagnosis is possible when the diagnosis is based on both the morphologic changes in tissues (traditional anatomic pathology) and on molecular testing.[2] It is a scientific discipline that encompasses the development of molecular and genetic approaches to the diagnosis and classification of human diseases, the design and validation of predictive biomarkers for treatment response and disease progression, the susceptibility of individuals of different ...
A tailored therapeutic approach and personalized medicine has become the norm rather the future of medicine, and pharmaceutical companies need a platform that can 1) perform multimodal complex assays, 2) perform quantitative assays, and 3) perform multiplex assays. High Multiplex, Multimodal qPCR is the next generation of Molecular Diagnostics. The ICEPlex System fulfills all three specifications for a platform that can be used for Companion Diagnostics. ...
The Worldwide Molecular Diagnostics Equipment Market report offers the analyzed information of the showcase in ordered view. The Molecular Diagnostics Equipment Market offers a typical stage with different chances to numerous organizations, affiliations, enterprises, and different items and administration suppliers Roche Diagnostics, QIAGEN N.V., Abbott Laboratories, Hologic Inc., Grifols, Cepheid Inc., Genomic Health, Inc., Sequenom, Luminex Corporation, Myriad Genetics, Inc., Foundation Medicine, Inc., Natera inc. to contend among themselves by offering better items and satisfactory administrations to the customers and extend essentially at the worldwide level. The worldwide showcase report offers abridged insight concerning the significant market holding key contenders nearby the ongoing creating enterprises in the market identifying with the income, requests, deals, and item quality.. The present status and future viewpoint of the market development is additionally remembered for the ...
Molecular diagnostics use an individuals genetic code and gene expression to diagnose and monitor diseases. The technique is used increasingly in the field of infectious diseases and oncology, as well as areas such as coagulation, HLA typing and pharmacogenomics. Molecular diagnostics plays a pivotal role in personalized medicine.
Health,Dalla TX (PRWEB) May 19 2013 These molecular diagnostics market reports provide a comprehensive analysis for US UK Spain Japan Italy Germany and France: Major issues pertaining to the molecular diagnostics laboratory practice as well as key economic regulatory demographic social and technologi,Molecular,Diagnostics,Market,-,US,,UK,,Spain,,Japan,,Italy,,Germany,&,France,Analysis,in,New,Research,Report,at,ReportsnReports.com,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth. Moreover, increasing demand for rapid and accurate diagnostic devices for early validation of such diseases is further expected to enhance usage rates during the forecast period.. Increasing adoption of sedentary lifestyle coupled with decrease in immunity levels is expected to provide the market with a largetarget patient base. Growing awareness levels pertaining to prenatal genetic testing for early detection of developmental abnormalities and defects is also anticipated to increase penetration levels. Technological advancement on the grounds of accuracy, portability, and cost-effectiveness isalso expected to serve this market as a high impact rendering driver.. Full research report on molecular ...
2017-2021 Infectious Disease Molecular Diagnostics Market: Test Volume and Sales Forecasts, Supplier Shares, Competitive Strategies, Innovative Technologies, Instrumentation Review 2017-2021 Infectious Disease Molecular Diagnostics Market: - Market research report and industry analysis - 10642948
Molecular diagnostics is rapidly an evolving market supported by increasing R&D activities for biomarker identification coupled with emergence of new applications of these tests. Infectious disease alone captures 60% share of the total molecular diagnostics applications market and remaining one third is attributed to genetic testing and blood donor screening. The growth of this segment is driven by rising incidence of cervical cancer caused due to Human Papilloma Virus (HPV). HPV is known to be a causative agent for cervical cancers hence HPV testing is projected to have a CAGR of 14.8% during the forecast period of 2013-2019. Hospital acquired infections (HAI)is anticipated as the fastest growing segment within infectious diseases and is expected to show CAGR of 15.1% from 2013-2019. Oncology testing and HLA typing testing are also projected to grow at a rapid rate during the same forecast period ...
Production, means the output of Molecular Diagnostics in Cancer Testing Revenue, means the sales value of Molecular Diagnostics in Cancer Testing This repo
San Francisco, Sept. 13, 2016-- Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market.
Global Molecular Diagnostics Market: Overview Molecular diagnostics refers to a collection of techniques used to analyze biological markers in the individu
... MANSFIELD Mass. March 26 2013 /PRNewswire...Under the agreement Quest Diagnostics has rights to use the PrimeraDx...PrimeraDx will also have rights to develop and market in vitro...PrimeraDx launched the ICEPlex system in August 2011. The system...,PrimeraDx,to,Co-Develop,Companion,Diagnostics,with,Quest,Diagnostics,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
ICON is a leader in addressing US FDA and European IVDD (IVD Directive) regulatory and clinical trial requirements for in vitro diagnostic devices.